Cancer Nanotechnology

Basic,Translational and Clinical Research

Cancer Nanotechnology Cover Image
Open Access

Erratum to: Toxicogenomics of nanoparticulate delivery of etoposide: potential impact on nanotechnology in retinoblastoma therapy

  • Moutushy Mitra1, 4,
  • Fahima Dilnawaz2,
  • Ranjita Misra2,
  • Anju Harilal1,
  • Rama Shenkar Verma3,
  • Sanjeeb K. Sahoo2 and
  • Subramanian Krishnakumar1Email author
Cancer NanotechnologyBasic,Translational and Clinical Research20112:13

DOI: 10.1007/s12645-011-0013-9

Published: 15 March 2011

The original article was published in Cancer Nanotechnology 2010 2:10

Erratum to: Cancer Nano

DOI 10.1007/s12645-010-0010-4

Unfortunately section 2.13 was not included in the paper. The missing section is given below.

2.13 cDNA Microarray analysis

For microarray analysis, cells were seeded in 6-well plates (Corning, NY, USA) at 1 × 106 cells per well, and after 24 h, they were then treated with (0.0005 μg/ml) the drug either as a solution or encapsulated in nanoparticles for 5 days. Total RNA used for the microarray analysis was isolated from cultured cells using TRIZOL reagent (Invitrogen, USA) and purified using an RNeasy Mini Kit (Qiagen, USA) combined with DNase treatment following the manufacturer’s instructions. Total RNA (20 μg) was labeled using a Fluorescent Direct Label Kit (Agilent Technologies) and simultaneously reverse transcribed into cDNA. The labeled samples were cleaned with a QIAquick PCR purification kit (Qiagen, USA) and then hybridized to the Human Whole Genome 44K Oligo Microarray for 17 h at 65°C as recommended by the manufacturer (Agilent Technologies, USA). Data analysis was done using Genespring GX version 10. Agilent Feature Extraction software (G25677AA, Agilent Technologies, 2004) was used to analyze the microarray data. For the differentially regulated genes analysis, i.e., genes showing fold change of >1 (upregulated in etoposide-loaded nanoparticle-treated Y-79 cell lines compared to native etoposide-treated Y-79 cell lines) or less than −1 (downregulated in etoposide-loaded nanoparticle-treated Y-79 cell lines compared to native etoposide-treated Y-79 cell lines) were selected. The experiment was performed in triplicates.


Authors’ Affiliations

Department of Ocular Pathology, Vision Research Foundation
Institute of Life Sciences
Indian Institute of Technology
CeNTAB, Sastra University


© Springer-Verlag 2011